Member Announcements 2008

 

December 16, 2008

FDA Approves Genzyme’s Mozobil

 

December 15, 2008

Bull, Housser & Tupper: Linking Technology and Law

 

December 15, 2008

Biotech Essential to Economic Recovery

 

December 10, 2008

A better way to assess drugs, and provide them to those in need

 

December 4, 2008

OncoGenex shares jump on cancer drug test results

 

December 3, 2008

Drug Benefit Council Seeks Public Members

VICTORIA – The Province is seeking three members of the public to provide input on the medications provided to British Columbians under the PharmaCare drug insurance program, announced Health Services Minister George Abbott today.

 

December 3, 2008

Premier Opens World-Leading Spinal Cord Injury Centre

 

December 1, 2008

PROVINCE BACKS BIOFUELS TO REDUCE GHG EMISSIONS

 

December 1, 2008

Biolux Research Announces Commercial Launch of the OsseoPulseâ„¢ Bone Regeneration System in Korea.

 

November 28, 2008

New genomic tools will help sustain Pacific coastal ecosystems

 

November 26, 2008

World’s First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada
BELLEVILLE, ON, Oct. 27 /CNW/ – Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that Econiche(TM), the world’s first vaccine designed to reduce the
shedding by cattle of Escherichia coli (E. coli) O157:H7, has received full
licensing approval from the Canadian Food Inspection Agency (CFIA). Econiche
is now available for unrestricted use by Canadian cattle producers and their
veterinarians.

 

November 18, 2008

David Emerson Joins Farris as Senior Advisor
VANCOUVER – Farris, Vaughan, Wills & Murphy LLP (Farris), one of Canada’s leading law firms, today welcomes The Honourable David Emerson, P.C., formerly Canada’s Minister of Foreign Affairs, to the firm as Senior Advisor.

 

November 18, 2008

iCo Therapeutics Oral Amphotericin B Poster at AAPS

VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to report that iCo-009, the company’s oral Amphotericin B program, has been accepted for a poster presentation at the American Association of   Pharmaceutical Scientist (AAPS) Meeting in Atlanta, GA.

 

November 18, 2008

TRIUMF: Vancouver Scientists Help Solve World Isotope Dilemma

 

November 7, 2008

EnWave Initiates Final Commercial Testing Phase for Continuous nutraREV Food Dehydration Technology
Vancouver, B.C. – EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) today announced that it has completed its final modifications to its continuous commercial-scale nutraREV food dehydration equipment and has started the final testing phase at the blueberry processing facility of CAL-SAN Enterprises Ltd. in Richmond, B.C.

 

November 7, 2008

iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis

VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to report that oral administration of iCo-009, iCo’s oral formulation of Amphotericin B, displays a dramatic knock-down of a parasitic infection that causes Visceral Leishmaniasis (VL).   The studies were undertaken at an independent research laboratory in the United States with significant experience with VL animal models.

 

November 7, 2008

AMGEN OFFERS $10,000 SCIENCE TEACHING AWARD, CALLS FOR TEACHERS TO APPLY
MISSISSAUGA, ON. (Nov. 1, 2008) – Amgen Canada today announced that applications for the Amgen Award for Science Teaching Excellence (AASTE) are now open and is encouraging teachers in BC, Alberta, Ontario and Quebec to apply.   The AASTE is designed to recognize and honour teachers who demonstrate exemplary science teaching and who achieve demonstrated results in student learning at the K-12 level in Canada.

 

November 3, 2008

Zymeworks Appoints Noel Hall to Its Board of Directors

 

October 31, 2008

Biolux Research Announces Launch of the OsseoPulseâ„¢ Bone Regeneration System in Canada.
VANCOUVER, B.C., CANADA – Oct. 31, 2008 – Biolux Research Ltd. is pleased to announce today that it has launched the OsseoPulseTM Bone Regeneration System in Canada.   The product is now available for sale through Citagenix Inc., our exclusive distribution partner.   The product has been approved by Health Canada as a class II medical device, and received a medical device license earlier in 2008.   Production quality has been proven, sales training has taken place, and product has been shipped to Citagenix to begin marketing and sales.

 

October 31, 2008

Zymeworks Appoints Dr. Richard Lavery to its Scientific Advisory Board

 

October 30, 2008

Welichem Reports Positive Phase IIa Clinical Results
BURNABY, BC, Oct. 30, 2008  – Welichem Biotech Inc. (the “Company”) (TSX-V: WBI) is pleased to announce the positive results from its Phase IIa clinical trial of its drug candidate, WBI-1001, a new, non-steroid, topical cream treatment for atopic dermatitis (AD). In the trial, two concentrations (0.5% and 1.0%) of WBI-1001 were tested against the placebo. Both WBI-1001 cream concentrations were superior
to placebo in deceasing AD and showed an excellent safety profile. Welichem plans to conduct further clinical trials for WBI-1001 in 2009. “We are very pleased to be able to present such positive results from the Company’s clinical trial on atopic dermatitis,” says Dr. Genhui Chen, Chief Executive Officer of Welichem.” AD is a major unmet medical indication, and these positive results are of significance for our overall strategy of developing WBI-1001 for the treatment of this disease and additional conditions.”

 

October 28, 2008

Science Opportunities Knock for BC Researchers
Genome British Columbia has announced the results of the first Science Opportunities Fund competition in which nine awards have been made to researchers in the Province with a total approved budget of $2.3 million.   The nine teams of researchers located in Vancouver, the Okanagan and on Vancouver Island are launching peer-reviewed, short-term research projects the results of which will have impacts on important sectors of BC’s economy and environment.

 

October 22, 2008

ICE Fund: Further $25M Dedicated to Rural Clean Energy Projects

 

October 16, 2008

TOP CANADIAN BIOTECHNOLOGY TEACHER: ALBERT CHANG FROM VANCOUVER RECEIVES AWARD FOR TEACHING EXCELLENCE IN LIFE SCIENCES

 

October 14, 2008

Zymeworks Appoints Dr. Michael J. Gresser to its Scientific Advisory Board

 

October 9, 2008

iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results

VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce a series of positive experiments investigating the systemic bioavailability of amphotericin B following oral administration.   iCo-009 is iCo’s oral formulation of Amphotericin B, a broad spectrum antifungal drug which currently can only be delivered by intravenous (IV) infusion. Results indicate that oral administration of iCo-009 results in blood levels that are comparable to a known IV Amphotericin B product currently on the market.

 

October 6, 2008

Cobalt Engineering Clients Recognized by BC Hydro Power Smart

 

October 1, 2008

iCo Therapeutics Selected as Canada’s Top 10â„¢ Competition Winner
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO), a reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications, is pleased to announce that iCo has been selected as one of Canada’s Top 10â„¢ Competition winners. Top 10â„¢ winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. The panel can be viewed at http://www.topcanadiancompanies.ca/jury/ls_jury.html.

 

September 30, 2008

Lignol to Collaborate with Weyerhaeuser to Explore Commercial Development of Cellulose-based Products and Biochemicals
VANCOUVER, Sept. 30 – Lignol Energy Corporation (TSX-V: LEC) (“Lignol” or “the Company”), a leading technology company in the lignocellulosic biorefining sector, today announced that it has signed a Memorandum of Understanding (the “MOU”) with Weyerhaeuser Company (“Weyerhaeuser”) (NYSE: WY) to explore the development of commercial applications of biochemical outputs from Lignol’s proprietary biorefining technology.

 

September 29, 2008

iCo Therapeutics to Present at BioContact Quebec

VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO), a reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications, is pleased to announce that iCo will present at the BioContact Quebec 2008 conference.

 

September 25, 2008

EnWave Announces Additional Positive Shelf-Life Results from Vaccine Dehydration Testing
EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) today announced that it has received positive results from a second shelf-life study of dehydrated rotavirus vaccine conducted by its collaboration partner Aridis Pharmaceuticals, LLC (“ Aridis”) of San Jose, California using EnWave’s bioREV technology.

 

September 22, 2008

Upcoming conference to help sponsors work with CROs more effectively
Vancouver, Canada, September 22, 2008:   Contract research organizations (CROs) are a mainstay of clinical development.   When you outsource clinical development to CROs, you are taking one of the most expensive processes your company performs – a process upon which the future success of your company depends – and giving it to someone else to manage.   As a result, problems selecting and managing CROs can be expensive and put the future success of your company at risk.

 

September 22, 2008

iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)

VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to report interim results from iCo’s ongoing iCo-007 clinical trial. The phase I, open-label, dose escalation study is evaluating the safety, tolerability, and pharmacokinetics of a single intravitreal injection of iCo-007 in patients with diffuse diabetic macular edema (DME).

 

September 18, 2008

EnWave Corporation Announces Major Advancement in Pharmaceutical Dehydration Technology

EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) today announced that it has made a major innovation in its Radiant Energy Vacuum (“REV”) pharmaceutical dehydration technology to allow for a significant reduction in the moisture content of dried vaccine products.

 

September 15, 2008

Inimex Pharmaceuticals Honored Among This Year’s Most Promising Private Technology Ventures in Canada
 

 

September 9, 2008

2008 BC Innovation Council Award Winners Announced

 

September 4, 2008

iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial

 

July 22, 2008

New International Wine Genomics Project Launched

 

July 14, 2008

Genome BC Adds Three New Members to its Board of Directors

 

July 14, 2008

EnWave Installs Food Dehydration Technology in Saskatoon Berry Processing Plant
Vancouver, B.C. – EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) has successfully installed a batch unit of its proprietary food dehydration technology, nutraREV, into a Saskatchewan berry processing facility to test the machine’s ability to dehydrate Saskatoon berries into a commercially saleable product.

 

July 9, 2008

EnWave Produces Saleable Dried Blueberry Product from its Continuous nutraREV Technology
Vancouver, B.C.EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) today announced that it has achieved an important milestone by producing a saleable dried blueberry product using its continuous nutraREV dehydration equipment.

 

July 8, 2008

iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the addition of Mr. Noel Hall and Dr. Christian Fibiger to iCo’s Board of Directors.   Mr. Hall was most recently co-founder, President and Director of Aspreva Pharmaceuticals Corporation, which was acquired by the Galenica Group for $915M (USD) in January 2008.   Dr. Fibiger was most recently Vice President and Global Head of Neuroscience for Amgen Inc. and, during his academic career, was one of the top 100 most cited scientists in neuroscience.

 

July 8, 2008

Welichem Successfully Completes Phase I Clinical Trial
Welichem Biotech Inc. (the “Company”) (TSX-V: WBI) announces today  the successful completion of and the results from a randomized, double-blinded Phase I clinical trial done in Montreal, Canada, which evaluated topically applied WBI-1001 in 36 psoriasis patients.

 

July 7, 2008

Zymeworks Appoints Key Industry Leaders to its Scientific Advisory Board

 

July 7, 2008

ANGIOTECH TO ESTABLISH SEPARATE OPERATING AND ROYALTY BUSINESSES

 

June 26, 2008

iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results

VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to provide further preclinical results supporting the accelerated development of iCo-009, the company’s oral reformulation of Amphotericin B (Amp B). Amp B is a generic drug that has been in use for approximately 50 years, however its use is limited as it is currently administered intravenously and has significant infusion related side effects and kidney toxicity.

 

June 25, 2008

Hyaluron Contract Manufacturing (HCM) Announces Patent Approval

 

June 23, 2008

Unlocking the power of RFPs to improve CRO selection
Vancouver, Canada, June 23, 2008:   Many clinical-trial professionals sense they are not getting the best value out of contract research organizations (CROs), citing ambiguity in pricing, poor communication, waning commitment to projects and lack of strategic fit.

 

June 17, 2008

Forbes Medi-Tech Achieves “Minimum Bid Price Requirement” for Continued Listing on The Nasdaq Stock Market
Forbes Medi-Tech Inc. announced today that the Company has demonstrated compliance with Nasdaq’s Minimum Bid Price Requirement, as evidenced by a closing bid price of $1.00 or more for a minimum of ten consecutive trading days.

 

June 9, 2008

Forbes Medi-Tech Receives Extension to Achieve Nasdaq’s “Minimum Bid Price Requirement”
The Company annouced today that the Nasdaq Hearings Panel has granted the Company an extension through June 30, 2008, to demonstrate compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Stock Market.

 

June 9, 2008

Pyng Medical Closes Acquisition of Bio Cybernetics’ Trauma Assets
Vancouver, BC Pyng Medical Corp. (PYT: TSX .V) today announced it has completed the acquisition of the trauma assets of California-based Bio Cybernetics International (BCI) (dba “Cybertech Medical”, www.cybertechmedical.com), including the market leading Trauma Pelvic Orthotic Device (TPOD ®), Mechanical Advantage Tourniquet (MAT ®), and Cricothyrotomy Kit (CRICâ„¢).

 

June 6, 2008

Harrison Clinical Research and ASKA Research announce Strategic Alliance
[Munich, Germany and Vancouver, Canada; June, 2008] Harrison Clinical Research (HCR) and ASKA Research (ASKA) are proud to announce that they have agreed on a formal strategic alliance to expand the global reach of both companies and to better serve their clients in all aspects of global drug and medical device development, education services, and clinical trial management.

 

June 5, 2008

Pacgen Announces Positive Results From Phase IIb Dose-Ranging Trial of PAC-113
Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX VENTURE: PGA) today announced positive results from its Phase IIb dose-ranging trial of PAC-113, a novel anti-fungal drug candidate.

 

June 3, 2008

Zymeworks’ ZymeCADâ„¢ platform for protein engineering to be evaluated by DSM

 

June 3, 2008

EnWave Engages European Investor Relations Firm
Vancouver, B.C. – EnWave Corporation (TSX-V: ENW) (“EnWave”, or the “Company”), has engaged the services of AXINO AG (“AXINO”) of Stuttgart, Germany to undertake investor relations activities for the Company in Germany and other European countries. AXINO is an investor relations agency providing a wide range of services to companies to help broaden investor exposure, develop a shareholder following and identify financing opportunities in the European financial markets.

 

June 2, 2008

OncoGenex Reports that Low Serum Clusterin Levels were Predictive of Survival in Preliminary Analyses of Phase 2 Study of Lead Drug Candidate OGX-011
VANCOUVER, British Columbia, Canada – June 2, 2008 – OncoGenex Technologies Inc. announced today that the Company’s lead cancer drug candidate, OGX-011, continues to show better than expected survival results in patients with hormone refractory prostate cancer (HRPC) when compared to published results.  OGX-011, also referred to as custirsen sodium, is a second-generation antisense oligonucleotide designed to facilitate tumor cell death induced by chemotherapy by decreasing production of clusterin, a cell survival protein linked to treatment resistance.  Preliminary analyses have shown that low-average levels of serum clusterin were predictive of the survival benefit.   Additionally, patients treated with second-line chemotherapy plus OGX-011 experienced a reduction in pain that was durable as well as a decline in PSA. These data were presented by Dr. Fred Saad, Professor of Surgery/Urology at the University of Montreal, on June 1 at the 2008 Annual Meeting of the American Society of Clinical Oncology. OncoGenex and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) are collaborating on development of OGX-011.

 

June 2, 2008

Inimex Raises US $22 Million in the Fight Against Antibiotic Resistance

 

June 2, 2008

Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Completion of Business Combination

-$10.0 Million Private Placement with Alnylam Pharmaceuticals and Roche Completed-

 

June 2, 2008

EnWave Closes Private Placement
Vancouver, B.C. – EnWave Corporation (TSX-V: ENW) (“EnWave”, or the “Company”), wishes to announce the closing of the non-brokered private placement originally announced on May 06, 2008. The placement has raised $1,065,150 by issuing 3,550,501 units at a price of $0.30 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles its holder to purchase one common share of the Company at a price of $0.45 per share until May 30, 2010.

 

May 28, 2008

Sonus Pharmaceuticals and OncoGenex Technologies to Merge
BOTHELL, Washington and VANCOUVER, British Columbia – May 28, 2008 – Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) and OncoGenex Technologies Inc., a privately held biopharmaceutical development company, today jointly announced the signing of a definitive agreement to merge the two companies. The combined company will operate as OncoGenex Pharmaceuticals, Inc.   Scott Cormack, OncoGenex’ current President and Chief Executive Officer will continue as President and CEO of the company.   As a result of the merger, the combined company will have a strong oncology pipeline addressing distinct unmet needs in the treatment of cancer, including three candidates in various stages of clinical development. Its lead candidate, OGX-011, is being evaluated in five Phase 2 clinical trials, each of which has completed patient enrollment.   Interim study results have previously been presented for each of the five clinical trials.

 

May 22, 2008

Forbes Medi-Tech Restructures Board by Reducing Number of Directors from Six to Four – Greg Anderson Appointed as Director and Joe Dunne Named as Chair
The Company today announced that Greg Anderson was appointed to the Company’s Board of Directors and Dr. Joe Dunne was named as Chairman.   As approved at the Company’s Annual General Meeting (“AGM”), the current composition of Forbes’ Board is now fixed at four Directors and includes Dr. Joe Dunne, Nitin Kaushal, Greg Anderson, and Charles Butt

 

May 20, 2008

FutureWorks launches WorkStart funding program to hire young people

 

May 15, 2008

Forbes Medi-Tech Announces Corporate Restructuring – Company To Focus Exclusively on Core Nutraceutical Business and Reduce 2008 Research and Development Expenses by Approximately $2.7 Million
The Company today announced a plan to focus exclusively on its revenue-generating nutraceutical business, which includes functional foods and dietary supplements, and cease all in-house drug development activities.

 

May 14, 2008

Forbes Medi-Tech Announces First Quarter 2008 Financial Results
The Company today announced its results for the first quarter 2008 ended March 31, 2008.

 

May 14, 2008

EnWave Partners with Saskatoon Berry Producer to Test Novel Dehydration Technology
Vancouver, B.C. – EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) has announced the lease of a batch unit of its proprietary food dehydration technology, nutraREV, to a Saskatoon, Saskatchewan-based berry processing company, Riverbend Plantation, Inc. The company will test the feasibility of using nutraREV to dehydrate Saskatoon berries into a commercially saleable product for the North American and European markets.

 

May 12, 2008

Forbes Medi-Tech Announces Completion of $3.8 Million Non-Dilutive Funding Transaction
The Company today announced that, as part of its continuing reorganization plan, it has completed the previously announced transaction with a private investor (the “Investor”) to reorganize Forbes Medi-Tech Operations Inc. (“FMTO”), a wholly owned subsidiary of Forbes.

 

May 7, 2008

EnWave Changes Terms of Private Placement
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave”, or the “Company”), further to its May 6, 2008 press release, wishes to announce that it has changed some of the terms of the non-brokered private placement. The offer will be for up to 3,000,000 units at a price of $0.30 per unit. Each unit will now consist of one common share and one whole share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of $0.45 per share for a period of two years from the time of issuance of the units. All of the other terms of the placement remain unchanged.

 

May 6, 2008

EnWave Announces Private Placement
Vancouver, B.C.-EnWave Corporation (TSX-V: ENW) (“EnWave”, or the “Company”) wishes to announce that it has agreed to a non-brokered private placement of up to 2,750,000 units at a price of $0.30 per unit. Each unit will consist of one common share and one half share purchase warrant. Each whole warrant will entitle the holder to purchase one common share at an exercise price of $0.45 per share for a period of two years from the time of issuance of the units. The proceeds of up to $825,000 will be used for the ongoing development of EnWave’s Radiant Energy Vacuum (bioREV,nutraREV, and powderREV) technologies,   working capital and for general corporate purposes.

 

May 2, 2008

CTI Clinical Trial and Consulting Services and ASKA Research Announce Global Collaboration

 

May 1, 2008

Diversified Bio-Medics, Inc. signs signed Mutual Non-Disclosure Agreement (MNDA) with Pall Corporation

 

May 1, 2008

EnWave Receives Positive Shelf-Life Results from Vaccine Dehydration Testing
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave” or the “Company”) is pleased to report that it has received positive results from the Company’s first room temperature shelf-life study of dehydrated rotavirus vaccine conducted by its collaboration partner Aridis Pharmaceuticals, LLC (“Aridis”) of San Jose, California. The Company believes it is now one step closer to developing a new industry standard technology for dehydrating vaccines and antibodies.

 

April 29, 2008

Neuromed Names Sean Cunliffe Chief Commercial Officer
Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, today announced the promotion of Sean Cunliffe to Chief Commercial Officer.

 

April 24, 2008

Forbes Medi-Tech Announces Pharmavite Contract Renewal ~Following Strong Volume Growth in 2007, the Company Looks to Further Expand Product Line with Reducol TM-Based Products~
The Company today announced it has extended its supply and licensing contract with Pharmavite LLC until mid 2009 for the continued sale of Reducol TM, the branded cholesterol lowering ingredient in one of Pharmavite’s leading line of dietary supplements, Nature Made ® CholestOff ® and CholestOff ® Complete.

 

April 21, 2008

EnWave Corporation Provides Update on Development and Commercialization of Novel Dehydration Technology
Vancouver, B.C.- EnWave Corporation (TSX-V:ENW) (“EnWave” or the “Company”) is pleased to provide a corporate update to shareholders regarding the development and testing of its Radiant Energy Vacuum (REV) technology in the medical and food sectors.

 

April 17, 2008

Ernst & Young to Honour Canada’s Entrepreneurial Excellence Nominations are now being accepted for the 15th annual Ernst & Young Entrepreneur Of The Year ® Awards

 

April 15, 2008

Finally, a business research and communication service specifically for the life-science industry
Vancouver, Canada, April 15, 2008 – As BC life-science companies continue to commercialize innovative technologies, many firms have a growing need to analyze and communicate complex business issues to a variety of stakeholders, including investors, partners and senior management.

 

April 1, 2008

Forbes Medi-Tech now Trading under former NASDAQ Trading Symbol ‘FMTI’

 

March 31, 2008

Forbes Medi-Tech announces Fincnacial Results for the Year ended December 31, 2007 ~Company Achieves 2007 Revenue Guidance; FY2007 Revenue up 45%~
The Company today announced its financial results for the year ended December 31, 2007 versus the year ended December 31, 2006.   All amounts are in Canadian dollars unless otherwise noted.

 

March 20, 2008

Forbes Medi-Tech Announces $3.8 Million Non-Dilutive Funding Transaction
The Company today announced that, as part of its continuing reorgainztion plan, it has entered into an agreement with a private investor (the “Investor”) to reorganize Forbes Medi-Tech Operations Inc. (“FMTO”), a wholly-owned subsidiary of Forbes.

 

March 19, 2008

Forbes Enters Into New Collaboration for Reducol in Germany, Austria and Switzerland
The Company today announced that it has entered into collaboration wiht Max food ingredients GmbH, a member of the Uplegger food company GmbH group.

 

March 17, 2008

iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that iCo-009 has been highlighted in a leading drug delivery journal, Advanced Drug Delivery Reviews. The paper discusses the development of a novel oral Amphotericin B (AmpB) formulation (“iCo-009”) with significant antifungal activity, minimal kidney toxicity, and enhanced oral absorption of AmpB.

 

March 11, 2008

EnWave Corporation Receives Promising Results on Dehydration of Probiotics and Enzymes. Company Plans New Bulk Powder Prototype

 Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave” or the “Company”) today announced that it has successfully applied its Radiant Energy Vacuum (REV) technology to dehydrate probiotics and enzymes used in the food and fine biochemical industries.

 

March 10, 2008

iCo Therapeutics Provides iCo-008 Phase II Clinical Update
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to provide a clinical update on iCo-008, a human monoclonal antibody targeting eotaxin-1. iCo licensed iCo-008 from MedImmune of Cambridge, UK (formerly Cambridge Antibody Technology). iCo-008 has been in 126 patients in Phase I and II clinical trials.

 

March 10, 2008

Laborie Medical Technologies Receives FDA 510(k) Clearance for Tetraâ„¢ Bladder Monitor System

Laborie Medical Technologies Receives FDA 510(k) Clearance for Tetraâ„¢ Bladder Monitor System

FDA Approval Paves the Way for Commercial Launch of Urodynamix’s NIRS Technology

VANCOUVER, British Columbia, March 10, 2008 – Urodynamix Technologies Ltd. (TSX-V:URO) today announced that its worldwide distribution partner, Laborie Medical Technologies Inc. (Laborie) has obtained 510(k) clearance from the U.S. Food and Drug Administration to market their urodynamic equipment with the Tetraâ„¢ Bladder Monitor System for non-invasive bladder testing.

 

 

March 10, 2008

Italy’s Fiave Launches Premium Brand Natural Products with Reducolâ„¢ ~First Brand Name Product Launch in Europe~
The Company today announced that Fiave of Italy, one of the country’s premium dairy producers, has launched a yogurt drink containing Forbes’ cholesterol-lowering ingredient, Reducolâ„¢. The launch marks the first brand name product launch in Europe featuring Reducolâ„¢.

 

March 10, 2008

Government of Canada Invests $800,000 in Research at Genome BC

 

March 6, 2008

EnWave Provides Progress Report on Aridis Collaboration Testing of Vaccine Dehydration Technology
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave” or the “Company”) today reported that Aridis Pharmaceuticals, LLC (“Aridis”) of San Jose, California has completed its first testing stage of the bioREV technology for use as a vaccine and antibody dehydration method.

 

March 5, 2008

Urodynamix Signs Collaborative Agreement for NIRS Prostate Treatment Device
VANCOUVER, British Columbia, March 3, 2008 – Urodynamix Technologies Ltd. (TSX-V:URO) today announced that it has entered into a collaborative agreement for the further study of its NIRS technology that could significantly improve the treatment of symptomatic benign prostatic hyperplasia, or BPH (enlarged prostate). Urodynamix has entered into an agreement to evaluate a device incorporating its NIRS sensors with existing transurethral microwave thermotherapy (TUMT) devices for the minimally invasive treatment of BPH

 

March 3, 2008

Forbes Medi-Tech Announces Trading of Common Shares on Post-Exchange Basis
The Company today announced that its common shares are now trading on NASDAQ and the TSX on a post-exchange basis. Initially, the trading symbol for Forbes’ shares trading on NASDAQ will be “FMTID”, – an interim symbol to denote the post-exchange status. The trading symbol “FMI” for Forbes’ shares trading on the TSX remains unchanged.

 

March 2, 2008

Zymeworks Inc. announces closing of financing and addition to its board of directors

 

February 28, 2008

EnWave Partner Begins Commercial Testing of Innovative Food Dehydration Technology at Richmond, B.C. Blueberry Plant
February 28, 2008 –   Vancouver, B.C. – EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) today announced that after a successful test period at their Vancouver laboratory, the Company’s first continuous unit using its proprietary   food dehydration technology has been installed in a commercial food processing facility in Richmond, B.C. to test large-scale production capabilities.

 

February 27, 2008

iCo Therapeutics Announces Chief Medical Officer Invited to Present at International Ocular Conference

 

February 26, 2008

Forbes Medi-Tech establishes Exchange Ratio for Corporate Reorganization
The Company today announced that its Board of Directors has set the share exchange ratio for the Company’s corporate reorganization, which is to proceed by way of a plan of arangement (the “Arrangement”), at eight existing common shares of Forbes for one new common share.

 

February 26, 2008

Urodynamix Develops Next Generation NIRS Prostate Monitoring System

 

February 20, 2008

Scientists at the Providence Heart + Lung Institute receive $15 million to help prevent organ failure

 

February 15, 2008

Medical Ventures GAAME clinical update

 

February 15, 2008

OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer

 

February 14, 2008

Forbes Medi-Tech Issues Results from Special General Meeting -Resolutions Approved by Security Holders-
The Company today announced that securityholders have approved the Company’s corporate reorganization. For resolutions one and two, ‘Reduction in Stated Capital’ and ‘Name Change’ respectively, over 88% of votes cast were in favor of the resolutions. For resolution three, the ‘Plan of Arrangement’, over 82% of votes cast were in favor. Prior to the meeting, the plan of arrangement was amended to broaden the range of the exchange ratio for Forbes Medi-Tech shares to a range of two to eight Forbes shares for each Newco share. The exchange ratio was adjusted in light of recent market prices, and to provide flexibility to the Board of Directors in an effort to help regain compliance with Nasdaq’s minimum US$1 bid requirement. The actual exchange ratio will be announced as soon as it is set by the Board and will affect share, option and warrant holders equally.

 

February 8, 2008

PHARMENG names John Carkner as President, Keata Pharma – Arnprior, Ontario Facility

 

February 7, 2008

Forbes Medi-Tech Forecsts Strong Revenue Growth in 2008

 

February 6, 2008

Xenon Announces Appointment of VP, Discovery Research

 

January 31, 2008

ISS Recommends Forbes Medi-Tech Shareholders Vote ‘FOR’ the Proposed Corporate Reorganization
The Company announced today that Institutional Shareholder Services Inc. (ISS) has formally recommended that their clients holding shares in Forbes Medi-Tech vote “FOR” the proposed corporate reorganization. ISS, one of the world’s leading providers of corporate governance and proxy voting solutions, conducted an independent and comprehensive analysis of Forbes’ proposed corporate reorganization and its impact on shareholders.